Fig. 2From: Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trialTrial profile. IP Initial protocol, AP Amended protocol, ITT Intention to treat, PP Per protocol, * Major protocol deviationsBack to article page